Cwm LLC Cuts Position in HealthEquity, Inc. (NASDAQ:HQY)

Cwm LLC lowered its stake in shares of HealthEquity, Inc. (NASDAQ:HQY) by 8.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,635 shares of the company’s stock after selling 323 shares during the period. Cwm LLC’s holdings in HealthEquity were worth $298,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of HealthEquity during the 2nd quarter valued at approximately $35,000. Fidelis Capital Partners LLC purchased a new position in HealthEquity in the 1st quarter valued at approximately $42,000. GAMMA Investing LLC raised its holdings in HealthEquity by 114.8% during the second quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after purchasing an additional 318 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in HealthEquity during the second quarter worth $73,000. Finally, Headlands Technologies LLC purchased a new stake in HealthEquity during the first quarter worth $130,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the sale, the insider now directly owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other HealthEquity news, Director Frank Corvino sold 1,247 shares of HealthEquity stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the transaction, the director now directly owns 4,823 shares of the company’s stock, valued at $387,093.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the sale, the insider now directly owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,497 shares of company stock valued at $3,579,769. Insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

HQY has been the subject of several research reports. Bank of America cut their price target on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Royal Bank of Canada restated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft increased their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. JMP Securities restated a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Barrington Research reiterated an “outperform” rating and set a $105.00 target price on shares of HealthEquity in a report on Friday, September 20th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, HealthEquity has an average rating of “Buy” and a consensus target price of $103.83.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $87.74 on Tuesday. The company has a market cap of $7.63 billion, a P/E ratio of 95.37, a P/E/G ratio of 1.31 and a beta of 0.52. The business has a fifty day simple moving average of $79.11 and a 200-day simple moving average of $79.51. HealthEquity, Inc. has a 52 week low of $61.81 and a 52 week high of $89.23. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. The company had revenue of $299.93 million during the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. Equities research analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.